First patient dosed in first-in-human study evaluating BI 4060107 in people with advanced solid tumors Clinical development milestone triggers a payment to AimedBio under the companies’ 2025 global licensing agreement “Dosing the first patient marks an important step for BI 4060107, as the…
Boost ROI by outsourcing ADC production to one-stop CMOs, leveraging strategic partnerships and Asia-Pacific cost advantages to cut costs, accelerate timelines and scale efficiently. Dublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "ADC Contract Manufacturing Market (7th Edition): Distribution by Stage of Development, Process Component,…
Twelve years ago, Merck won FDA approval for the PD-1 inhibitor Keytruda, heralding a new era of cancer treatment—and opening the door to billions of dollars in revenue. Now, with immuno-oncology seemingly on the verge of its next breakthrough,…
Japan has the scientific expertise to develop new medicines, but high costs, fragmented hospital systems and limited global trial leadership are weakening its position. At BioJapan 2026, industry and regulatory experts outlined how faster evidence generation, international collaboration and AI-driven clinical…
Business Samsung Bioepis' first ADC candidate wins FDA Fast Track Published: Oct. 21, 2026 - 13:12:07 Samsung Bioepis said Wednesday that its first antibody-drug conjugate, or ADC, candidate has been designated a Fast Track drug by the US Food and Drug Administration. According to…
This is the second collaboration between the two companies in the ADC field. Editor’s Take: Leveraging the deep expertise of both Hansoh and Roche will benefit ADC advancement from early development through commercialization. Hansoh Pharma and Roche entered a strategic…
Roche will take ex-China development of Hansoh’s two preclinical ADCs and multiple programs against Roche-proposed targets once Hansoh completes global phase 1a trials. The deal includes $400 million upfront and more than $15 billion in potential milestones. “Exploring next generation ADCs is one…
Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VERAXA Biotech and Secarna Pharmaceuticals Achieve…
October 19, 2026 3:15 AM EDT | Source: Defence Therapeutics Inc. These achievements highlight the growing recognition of Defence's Accum® technology within the global ADC community. World ADC is a leading international scientific conference bringing together scientists, biotechnology innovators and pharmaceutical companies at the…
This presentation will teach you how to streamline and optimize ADC quantification with a Triple Quad mass spectrometer, using real-world examples of trastuzumab deruxtecan (TDx) in rat plasma. The speaker examines four complementary quantitative PK/PD assays, demonstrating how each…
ADCs: antibodies that carry toxic payloads to cancer cells, new linkers and payloads, their trials and approvals, and the ADC deal boom.
An article joins this feed when it matches these terms. Each one is also a search of its own.